Table 1 Comparison of demographics and treatment between patients with MCD, FSGS, and MN.

Age of onset (yrs)

31 (16, 49)

39 (19, 55)

60 (49, 69)

 < 0.001^a,b,c

Age at renal biopsy (yrs)*

34 (20, 50)

41 (24, 58)

61 (51, 70)

 < 0.001^a,b,c

Age of enrollment (yrs)

42 (29, 56)

47 (33, 62)

67 (58, 74)

 < 0.001^a,b,c

Male, n (%)

1899 (57.5%)

378 (57.5%)

911 (64.0%)

 < 0.001^b,c

Present treatment

 Oral PSL

2881 (87.2%)

530 (80.9%)

1104 (77.5%)

 < 0.001^a,b

 IV mPSL

256 (7.7%)

73 (11.1%)

42 (2.9%)

 < 0.001^a,b,c

 Cyclosporine

1559 (47.2%)

337 (51.5%)

621 (43.6%)

0.003^c

 Tacrolimus

51 (1.5%)

26 (4.0%)

15 (1.1%)

 < 0.001^a,c

 Cyclophosphamide

16 (0.5%)

3 (0.5%)

20 (1.4%)

0.002^b

 Mizoribine

403 (12.2%)

81 (12.4%)

238 (16.7%)

 < 0.001^b,c

 MMF

86 (2.6%)

29 (4.4%)

1 (0.1%)

 < 0.001^a,b,c

 Rituximab

199 (6.0%)

38 (5.8%)

10 (0.7%)

 < 0.001^b,c

 PSL + cyclosporine

1395 (42.2%)

299 (45.6%)

525 (36.9%)

 < 0.001^b,c

Dosage of present treatment

 Oral PSL (mg/day)

21.2 ± 17.8

20.0 ± 16.9

18.8 ± 15.4

0.001^b

 IV mPSL (mg/day)

568.7 ± 316.5

557.5 ± 219.7

558.7 ± 241.9

0.993

 Cyclosporine (mg/day)

97.0 ± 40.8

95.8 ± 42.4

93.7 ± 46.0

0.149

 Tacrolimus (mg/day)

2.4 ± 1.0

3.3 ± 2.1

2.5 ± 0.6

0.099

 Cyclophosphamide (mg/day)

76.6 ± 33.5

83.3 ± 57.7

65.0 ± 22.1

0.349

 Mizoribine (mg/day)

150.8 ± 66.2

148.3 ± 68.4

138.0 ± 42.7

0.144

 MMF (mg/day)

1459.3 ± 521.4

1456.9 ± 586.4

750

0.359

 Rituximab (mg/month)

594.3 ± 407.5

811.2 ± 612.9

511.1 ± 33.3

0.112

Steroid‑resistant NS

213 (6.4%)

236 (36.0%)

540 (37.9%)

 < 0.001^a,b

SDNS or FRNS

2320 (70.2%)

265 (40.5%)

351 (24.6%)

 < 0.001^a,b,c

Persistent proteinuria ≥ 0.5 g/gCr

583 (17.6%)

326 (49.8%)

828 (58.1%)

 < 0.001^a,b,c